Gray J M, Lawson D H, Boddy K, East W
Scott Med J. 1983 Apr;28(2):172-5. doi: 10.1177/003693308302800216.
Measurements of potassium status were reviewed in 23 hypertensive patients receiving metoprolol either alone or in combination with chlorthalidone or chlorthalidone plus potassium over an average period of nine months. There was no statistically significant change in plasma potassium, total blood cell or total body potassium in patients on long-term metoprolol. Four subjects (17%) in the diuretic groups developed hypokalaemia (serum potassium less than 3.0 mmol/l) in the absence of significant falls in total blood cell or total body potassium. Thus the use of chlorthalidone plus potassium did not provide adequate prophylaxis against hypokalaemia even in metoprolol recipients. The study confirms that monitoring parameters of potassium handling is still necessary in beta-blocker recipients who also receive diuretics alone or in a fixed-dose combination with potassium.
对23例高血压患者的钾状态测量进行了回顾，这些患者单独服用美托洛尔，或与氯噻酮联用，或服用氯噻酮加钾，平均疗程为9个月。长期服用美托洛尔的患者血浆钾、全血细胞或总体钾均无统计学上的显著变化。利尿剂组中有4名受试者（17%）出现低钾血症（血清钾低于3.0 mmol/L），而全血细胞或总体钾并无显著下降。因此，即使对于服用美托洛尔的患者，使用氯噻酮加钾也不能充分预防低钾血症。该研究证实，对于单独服用利尿剂或与钾联用固定剂量利尿剂的β受体阻滞剂使用者，监测钾处理参数仍然是必要的。
